Question to the Department of Health and Social Care:

To ask His Majesty's Government, in view of the advancing mpox epidemic, especially clade Ib, and given that a recent study has found that the effect of Imvanex wanes to undetectable levels after one year, to what extent His Majesty's Government hold a mixed stockpile of the three globally approved vaccines.

Of the three vaccines, Imvanex is the only one licensed in the United Kingdom by the Medicines and Healthcare products Regulatory Agency, and in the European Union by the European Medicines Agency, for active immunisation against smallpox, Mpox, and other diseases caused by the vaccinia virus in adults.

Imvanex is the only currently available vaccine with real world evidence of protection against Mpox. The Joint Committee on Vaccination and Immunisation has agreed that the evidence it has reviewed is consistent with protection from Imvanex being maintained for approximately 10 years.